Worldwide patterns of bronchodilator responsiveness: Results from the Burden of Obstructive Lung Disease study

Thorax

Volumn 67, Issue 8, 2012, Pages 718-726

  Tan, Wan C ^a   Vollmer, William M ^b   Lamprecht, Bernd ^c   Mannino, David M ^d   Jithoo, Anamika ^e   Nizankowska Mogilnicka, Ewa ^f   Mejza, Filip ^f   Gislason, Thorarinn ^g   Burney, Peter G J ^e   Buist, A Sonia ^h  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b CENTER FOR HEALTH RESEARCH   (United States)

^c PARACELSUS MEDICAL UNIVERSITY   (Austria)

^d UNIVERSITY OF KENTUCKY   (United States)

^e IMPERIAL COLLEGE LONDON   (United Kingdom)

^f JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

^g LANDSPITALI UNIVERSITY HOSPITAL   (Iceland)

^h OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

SALBUTAMOL;

ADULT; AFRICA; AIRWAY OBSTRUCTION; ARTICLE; ASIA; BRONCHODILATOR RESPONSE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; DRUG MECHANISM; EUROPE; FEMALE; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; HUMAN; LUNG FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; NORMAL VALUE; NORTH AMERICA; PRACTICE GUIDELINE; PREDICTIVE VALUE; PRIORITY JOURNAL; REFERENCE VALUE; SPIROMETRY;

EID: 84864016731     PISSN: 00406376     EISSN: 14683296     Source Type: Journal    
DOI: 10.1136/thoraxjnl-2011-201445     Document Type: Article

References (35)

1. Calverley PM, Burge PS, Spencer S, et al. Bronchodilator reversibility testing in chronic obstructive pulmonary disease. Thorax 2003;58:659-64. (Pubitemid 36976273)
2. Dompeling E, van Schayck CP, Molema J, et al. A comparison of six different ways of expressing the bronchodilating response in asthma and COPD: reproducibility and dependence of prebronchodilator FEV1. Eur Respir J 1992;5:975-81.
3. Nicklaus TM, Burgin WW Jr, Taylor JR. Spirometric tests to diagnose suspected asthma. Am Rev Respir Dis 1969;100:153-9.
4. Tashkin DP, Celli B, Decramer M, et al. Bronchodilator responsiveness in patients with COPD. Eur Respir J 2008;31:742-50.
5. Anthonisen NR, Lindgren PG, Tashkin DP, et al. Bronchodilator response in the lung health study over 11 yrs. Eur Respir J 2005;26:45-51. (Pubitemid 40945930)
6. Hansen EF, Vestbo J. Bronchodilator reversibility in COPD: the roguish but harmless little brother of airway hyperresponsiveness? Eur Respir J 2005;26:6-7. (Pubitemid 40945924)
7. Vestbo J, Edwards LD, Scanlon PD, et al. Changes in forced expiratory volume in 1 second over time in COPD. N Engl J Med 2011;365:1184-92.
8. Brand PL, Quanjer PH, Postma DS, et al. Interpretation of bronchodilator response in patients with obstructive airways disease. The Dutch Chronic Non-Specific Lung Disease (CNSLD) Study Group. Thorax 1992;47:429-36.
9. Eliasson O, Degraff AC Jr. The use of criteria for reversibility and obstruction to define patient groups for bronchodilator trials. Influence of clinical diagnosis, spirometric, and anthropometric variables. Am Rev Respir Dis 1985;132:858-64. (Pubitemid 16247754)
10. Pellegrino R, Viegi G, Brusasco V, et al. Interpretative strategies for lung function tests. Eur Respir J 2005;26:948-68. (Pubitemid 41632054)
11. Lehmann S, Vollset SE, Nygaard HA, et al. Factors determining performance of bronchodilator reversibility tests in middle-aged and elderly. Respir Med 2004;98:1071-9. (Pubitemid 39317936)
12. Anon. Lung function testing: selection of reference values and interpretative strategies. American Thoracic Society. Am Rev Respir Dis 1991;144:1202-18.
13. Quanjer PH, Tammeling GJ, Cotes JE, et al. Lung volumes and forced ventilatory flows. Report Working Party Standardization of Lung Function Tests, European Community for Steel and Coal. Official Statement of the European Respiratory Society. Eur Respir J Suppl 1993;16:5-40.
14. Anon. Criteria for the assessment of reversibility in airways obstruction. Report of the Committee on Emphysema American College of Chest Physicians. Chest 1974;65:552-3.
15. Sourk RL, Nugent KM. Bronchodilator testing: confidence intervals derived from placebo inhalations. Am Rev Respir Dis 1983;128:153-7. (Pubitemid 13073555)
16. Tweeddale PM, Alexander F, McHardy GJ. Short term variability in FEV1 and bronchodilator responsiveness in patients with obstructive ventilatory defects. Thorax 1987;42:487-90. (Pubitemid 17097050)
17. Tweeddale PM, Merchant S, Leslie M, et al. Short term variability in FEV1: relation to pretest activity, level of FEV1, and smoking habits. Thorax 1984;39:928-32. (Pubitemid 15211831)
18. Dales RE, Spitzer WO, Tousignant P, et al. Clinical interpretation of airway response to a bronchodilator. Epidemiologic considerations. Am Rev Respir Dis 1988;138:317-20.
19. Kainu A, Lindqvist A, Sarna S, et al. FEV1 response to bronchodilation in an adult urban population. Chest 2008;134:387-93.
20. Lehmann S, Bakke PS, Eide GE, et al. Bronchodilator reversibility testing in an adult general population; the importance of smoking and anthropometrical variables on the response to a beta2-agonist. Pulm Pharmacol Ther 2006;19:272-80.
21. Buist AS, McBurnie MA, Vollmer WM, et al. International variation in the prevalence of COPD (the BOLD Study): a population-based prevalence study. Lancet 2007;370:741-50. (Pubitemid 47321907)
22. Buist AS, Vollmer WM, Sullivan SD, et al. The Burden of Obstructive Lung Disease initiative (BOLD): rationale and design. COPD 2005;2:277-83. (Pubitemid 40993302)
23. Crapo RO, Hankinson JL, Irvin C, et al. Standardization of spirometry, 1994 update. American Thoracic Society. Am J Respir Crit Care Med 1995;152:1107-36.
24. GOLD-Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. 2010 http://www.goldcopd.org/uploads/users/files/GOLDReport- April112011.pdf (accessed 25 Apr 2012).
25. Hankinson JL, Odencrantz JR, Fedan KB. Spirometric reference values from a sample of the general U.S. population. Am J Respir Crit Care Med 1999;159:179-87. (Pubitemid 29036522)
26. Hanania NA, Celli BR, Donohue JF, et al. Bronchodilator reversibility in COPD. Chest 2011;140:1055-63.
27. Kesten S, Rebuck AS. Is the short-term response to inhaled beta-adrenergic agonist sensitive or specific for distinguishing between asthma and COPD? Chest 1994;105:1042-5. (Pubitemid 24112787)
28. Anthonisen NR, Wright EC. Bronchodilator response in chronic obstructive pulmonary disease. Am Rev Respir Dis 1986;133:814-19. (Pubitemid 16116509)
29. Watanabe S, Renzetti AD Jr, Begin R, et al. Airway responsiveness to a bronchodilator aerosol. I. Normal human subjects. Am Rev Respir Dis 1974;109:530-7.
30. Enright PL, Beck KC, Sherrill DL. Repeatability of spirometry in 18,000 adult patients. Am J Respir Crit Care Med 2004;169:235-8. (Pubitemid 38114540)
31. Guyatt GH, Townsend M, Nogradi S, et al. Acute response to bronchodilator. An imperfect guide for bronchodilator therapy in chronic airflow limitation. Arch Intern Med 1988;148:1949-52.
32. Schermer T, Heijdra Y, Zadel S, et al. Flow and volume responses after routine salbutamol reversibility testing in mild to very severe COPD. Respir Med 2007;101:1355-62. (Pubitemid 46667657)
33. Walker PP, Calverley PM. The volumetric response to bronchodilators in stable chronic obstructive pulmonary disease. COPD 2008;5:147-52. (Pubitemid 351892735)
34. Hankinson JL, Bang KM. Acceptability and reproducibility criteria of the American Thoracic Society as observed in a sample of the general population. Am Rev Respir Dis 1991;143:516-21.
35. Pride NB, Vermeire P, Allegra L. Diagnostic labels applied to model case histories of chronic airflow obstruction. Responses to a questionnaire in 11 North American and Western European countries. Eur Respir J 1989;2:702-9.